Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Editorial
Nature Reviews Drug Discovery 7, 545 (1 July 2008) | doi:10.1038/nrd2631
Risks, returns and reassurance
Abstract
The ongoing debate on the creation of an abbreviated regulatory pathway for 'follow-on' versions of innovator biologics in the United States highlights questions about the current balance between incentives for innovation and price competition in general.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
